Patient Network

Social Support Groups for People who wants to share their Health Experiences

Contact US

Customize and select a Badge to display on your website.

Size

Color

Your badge

Finished Customizing Your Badge?

Spread the Word

Invite other people and help them improve their quality of life.

Badge

Loading…

Kify Foundation

Patient Network is supported by Kify Foundation

Yahoo Health News

Study: 'Smart bomb' drug attacks breast cancer

FILE - This undated file image provided in 2007 by the Duke University Department of Medicine shows a right breast MRI from a 55-year-old woman with extreme breast density. The superimposed arrow points to a 2 cm rapidly enhancing lesion which was later confirmed by biopsy to be invasive breast cancer. Doctors have successfully dropped the first "smart bomb" on breast cancer, using a drug to deliver a toxic payload to tumor cells while leaving healthy ones alone, doctors plan to report Sunday, June 3, 2012. (AP Photo/Duke University Department of Medicine, File) Doctors have successfully dropped the first "smart bomb" on breast cancer, using a drug to deliver a toxic payload to tumor cells while leaving healthy ones alone.


Study: 'Smart bomb' drug attacks breast cancer

FILE - This undated file image provided in 2007 by the Duke University Department of Medicine shows a right breast MRI from a 55-year-old woman with extreme breast density. The superimposed arrow points to a 2 cm rapidly enhancing lesion which was later confirmed by biopsy to be invasive breast cancer. Doctors have successfully dropped the first "smart bomb" on breast cancer, using a drug to deliver a toxic payload to tumor cells while leaving healthy ones alone, doctors plan to report Sunday, June 3, 2012. (AP Photo/Duke University Department of Medicine, File) Doctors have successfully dropped the first "smart bomb" on breast cancer, using a drug to deliver a toxic payload to tumor cells while leaving healthy ones alone.


Follow-up Avastin shown to benefit colon cancer patients

CHICAGO (Reuters) - Colorectal cancer patients treated with a follow-up round of Avastin fare better than those given chemotherapy alone after their disease has worsened, according to results of a large clinical trial. Avastin, sold by Roche, is approved as a first-line or second-line treatment for colorectal cancer, but not for both. Sales of the drug, also known as bevacizumab, totaled $5.3 billion Swiss francs ($5.5 billion) last year. ...

Armed antibody delays spread of certain breast cancers

CHICAGO (Reuters) - A study of Roche's experimental "armed antibody" found it extended the length of time breast cancer patients lived without their disease getting worse, marking the second successful pivotal trial in this new class of cancer drugs. The drug, TDM-1, uses Roche's antibody drug Herceptin to deliver a potent cell-killing payload developed by ImmunoGen directly into cancer cells, with the aim of boosting drug response while lowering the risk of side effects. ...

Allergies Linked to Higher Cancer Risk: Study

By JESSICA YARBER, M.D. Can allergies increase your risk of cancer? A new study out of University of Washington Fred Hutchinson Cancer Research Center suggests this may be the case. Specifically, the study found that patients with allergies may have a higher risk of developing...

© 2012   Created by Patient Network Team.

Contact US  |  Report an Issue  |  Terms of Service